The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PTCT | +69.18% | +28.02% | +5.06% | +303% |
| S&P | +14.5% | +93.32% | +14.09% | +322% |
PTC Therapeutics, Inc. is a biopharmaceutical company. It engages in discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.
An upbeat presentation helped highlight the potential for the company's leading drug to be commercially successful.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $178.88M | -4.2% |
| Gross Profit | $163.39M | -2.9% |
| Gross Margin | 91.35% | 1.2% |
| Market Cap | $3.87B | 65.0% |
| Market Cap / Employee | $4.12M | 0.0% |
| Employees | 939 | -5.6% |
| Net Income | -$64.85M | 34.6% |
| EBITDA | -$27.28M | -3.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.02B | 55.4% |
| Accounts Receivable | $196.13M | 4.8% |
| Inventory | 34.1 | 7.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $371.08M | -2.2% |
| Short Term Debt | $17.08M | 6.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 27.65% | 57.1% |
| Return On Invested Capital | -30.15% | 15.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$59.65M | 6.9% |
| Operating Free Cash Flow | -$58.33M | 18.4% |
| Metric | Q1 2025 | Q2 2025 | YoY Change | ||
|---|---|---|---|---|---|
| Price to Earnings | 7.83 | 7.00 | - | ||
| Price to Book | -2.91 | -3.29 | -3.61 | -20.83 | 694.34% |
| Price to Sales | 3.17 | 4.32 | 2.48 | 2.16 | -17.00% |
| Price to Tangible Book Value | -2.05 | -2.37 | -3.05 | -10.01 | 457.85% |
| Price to Free Cash Flow TTM | 6.35 | 5.47 | - | ||
| Enterprise Value to EBITDA | -49.27 | -300.26 | 2.83 | -81.24 | 29.81% |
| Free Cash Flow Yield | 15.7% | 18.3% | - | ||
| Total Debt | $400.21M | $389.30M | $389.62M | $388.17M | -1.86% |
PTCT earnings call for the period ending September 30, 2021.
PTCT earnings call for the period ending March 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
